This is a routine insider trade disclosure with no material impact. Monitor for any pattern of increased insider selling in future filings, but this single transaction is immaterial relative to Genmab's $33.7B market cap.
GMAB drugs
GMAB drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 12 $51.74entry
- T+1 · 4d ago −0.72%α −0.35% · $51.37
- T+2 · todayOpen
- T+5 · in 2d Pending
- T+20 · in 24d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Genmab filed a Form 6-K disclosing a sale of 1,071 shares by Executive Vice President and Chief Commercial Officer Bradley Bailey on November 11, 2026, at an average price of DKK 3,602.98 per share. This is a routine insider transaction disclosure with no material financial impact on the company.
Key Facts
- Bradley Bailey, EVP and Chief Commercial Officer, sold 1,071 shares on November 11, 2026
- Weighted average sale price was DKK 3,602.98 per share
- Transaction took place on NASDAQ Copenhagen
- Total proceeds approximately DKK 3.86 million (about $0.54 million at current exchange rates)
- This is a routine disclosure under EU Market Abuse Regulation Article 19
Financial Impact
Sale of 1,071 shares at DKK 3,602.98 average price, total proceeds ~DKK 3.86M (approximately $0.54M)
Risk Factors
- No material risks identified from this filing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001434265-26-000155 |
| Document: gmab_20261112x6kx3.htm | 0001434265-26-000155 |
| Document: 0001434265-26-000155-index-headers.html | 0001434265-26-000155 |
| Document: 0001434265-26-000155-index.html | 0001434265-26-000155 |
| Document: 0001434265-26-000155.txt | 0001434265-26-000155 |
| Earnings Context (Synthetic; results releases only) | 0001434265-26-000155 |
Track record
31 reports on GMAB
3 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +91.28% at T+60 after the Aug 6, 2026 report. 5 of 7 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $52.12 Now $51.57 −1.06% settles Dec 15
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $51.74 Now $51.57 −0.33% settles Dec 11
- Nov 12, 20264d ago 6-K Neutral 2/10 Viewing Entry $51.74 Now $51.57 −0.33% settles Dec 11
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $51.74 Now $51.57 −0.33% settles Dec 11
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $51.74 Now $51.57 −0.33% settles Dec 11
- Nov 10, 20266d ago 6-K Neutral 2/10 Entry $53.87 Now $51.57 −4.27% settles Dec 10
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $54.07 Now $51.57 −4.62% settles Dec 9
- Nov 5, 202611d ago 6-K Neutral 5/10 Entry $52.74 Now $51.57 −2.22% settles Dec 4
- Nov 4, 202612d ago Institutional Cluster Neutral 2/10 Entry $52.74 Now $51.57 −2.22% settles Dec 4
- Oct 28, 202619d ago 6-K Bullish 6/10 Entry $57.29 Now $51.57 −9.98% settles Nov 25
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers